<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ayu</journal-id><journal-id journal-id-type="iso-abbrev">Ayu</journal-id><journal-id journal-id-type="publisher-id">Ayu</journal-id><journal-title-group><journal-title>Ayu</journal-title></journal-title-group><issn pub-type="ppub">0974-8520</issn><issn pub-type="epub">0976-9382</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22661850</article-id><article-id pub-id-type="pmc">3361931</article-id><article-id pub-id-type="publisher-id">Ayu-32-536</article-id><article-id pub-id-type="doi">10.4103/0974-8520.96129</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>A comparative study of <italic>Vamana</italic> and <italic>Virechana Karma</italic> in the management of <italic>Sthula Pramehi</italic> w.s.r. to Type-2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pandey</surname><given-names>Rajeev Kumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Bhatt</surname><given-names>N. N.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Singhala</surname><given-names>T. M.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shukla</surname><given-names>V. D.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Ph.D Scholar, Department of Panchakarma, National Institute of Ayurveda, Jaipur, Rajasthan, India</aff><aff id="aff2"><label>2</label>Panchakarma Physician, Department of Panchakarma, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, India</aff><aff id="aff3"><label>3</label>Pathologist, Singhala Laboratory, Jamnagar, India</aff><aff id="aff4"><label>4</label>Professor and Head, Department Kaya Chikitsa, JS Ayurved Mahavidyalaya, Nadiad, Gujarat, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Rajeev Kumar Pandey, Plot no. A-64, Maa Bhawar Bhawan, Bramhapuri (Near Samrat Gate), Jaipur-302002, Rajasthan, India. E-mail: <email xlink:href="pandey.drrajeev@gmail.com">pandey.drrajeev@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2011</year></pub-date><volume>32</volume><issue>4</issue><fpage>536</fpage><lpage>539</lpage><permissions><copyright-statement>Copyright: &#x000a9; AYU (An International Quarterly Journal of Research in Ayurveda)</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>In the present study, <italic>Vamana</italic> and <italic>Virechana</italic> along with palliative treatment was given to patients of <italic>Sthula Prameha</italic> (Diabetes mellitus or DM). An attempt was made to compare and evaluate the role of <italic>Shodhana</italic> therapy (<italic>Vamana</italic> and <italic>Virechana</italic>). Total 47 patients of <italic>Sthula Pramehi</italic> were registered in this study, out of which 38 completed the treatment. The patients were divided into two groups, viz. <italic>Vamana</italic> with <italic>Shamana</italic> (Group A) and <italic>Virechana</italic> with <italic>Shamana</italic> (Group B). Eighteen patients completed the treatment in Group A and 20 in Group B. <italic>Neem giloy satva</italic> capsule was used as <italic>Shamana</italic> drug at a dose of 500 mg twice daily after meals for 30 days in both the groups. The efficacy of therapy was assessed based on relief in cardinal signs and symptoms and blood sugar, lipid profile and other biochemical parameters etc. The results showed that the <italic>Vamana</italic> provided better relief in signs and symptoms as well as on fasting blood sugar (FBS) and postprandial blood sugar (PPBS) in comparison to <italic>Virechana</italic>.</p></abstract><kwd-group><kwd><italic>Shamana</italic></kwd><kwd><italic>Shodhana</italic></kwd><kwd><italic>Sthula Pramehi</italic></kwd><kwd><italic>Vamana</italic></kwd><kwd><italic>Virechana</italic></kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>In <italic>Ayurveda</italic>, Acharya Charaka, has classified <italic>Prameha</italic> into two types, i.e. <italic>Sthula Pramehi</italic> and <italic>Krisha Pramehi</italic> or <italic>Santarpanajanya</italic> and <italic>Apatarpanajanya Pramehi</italic>. It can also be correlated with the classification given by Acharya Vagbhata, i.e. <italic>Dhatu Kshayajanya</italic> and <italic>Avaranajanya Prameha</italic>, respectively.</p><p>The factors which provoke the <italic>Vata</italic> directly cause <italic>Apatarpanajanya Prameha</italic> while the factors which provoke <italic>Kapha</italic> and <italic>Pitta</italic> cause <italic>Santarpanajanya Prameha</italic>. In <italic>Avaranajanya Prameha</italic>, <italic>Kapha</italic> is the predominant <italic>Dosha</italic>, while the important <italic>Dushyas</italic> are <italic>Meda</italic> and <italic>Kleda</italic>. In <italic>Avaranajanya Samprapti</italic>, vitiated <italic>Kapha</italic> and <italic>Pitta</italic> obstruct the path of <italic>Vata</italic>, causing its provocation. <italic>Samshodhana</italic> is the best treatment for the elimination of <italic>Doshas</italic>. Vagbhata has mentioned that <italic>Doshas</italic> should be eliminated through the nearest passage.[<xref ref-type="bibr" rid="ref1">1</xref>] For the <italic>Doshas</italic> lying in the upper and lower parts of body, <italic>Vamana</italic> and <italic>Virechana</italic> are the appropriate to eliminate vitiated <italic>Kapha</italic> and <italic>Pitta</italic> respectively. So, in the present study, <italic>Vamana</italic> and <italic>Virechana</italic> have been selected.</p><p><italic>Neem giloy satva</italic> has been selected for <italic>Shamana</italic> therapy in both the groups after <italic>Samsarjana Krama</italic>, as mentioned in Bhaisajya Ratnavali, <italic>Prameha Chikitsa Prakarana</italic>.[<xref ref-type="bibr" rid="ref2">2</xref>]</p><p>The efficacy of therapy is assessed based on relief in cardinal signs and symptoms and also blood sugar, lipid profile, and other biochemical parameters with <italic>Deha Bala</italic>, <italic>Agni Bala</italic>, and <italic>Chitta Bala</italic> as per Charaka.[<xref ref-type="bibr" rid="ref3">3</xref>]</p><sec id="sec2-1"><title>Aims and objectives</title><p>
<list list-type="bullet"><list-item><p>To assess the effect of <italic>Vamana</italic> in the management of <italic>Sthula Pramehi</italic>.</p></list-item><list-item><p>To assess the effect of <italic>Virechana</italic> in the management of <italic>Sthula Pramehi</italic>.</p></list-item><list-item><p>To compare the effect of <italic>Vamana</italic> and <italic>Virechana</italic> in the management of <italic>Sthula Pramehi</italic>.</p></list-item></list>
</p></sec></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>Patients with classical signs and symptoms of <italic>Sthula Pramehi</italic> (Type-2 Diabetes) were selected from the O.P.D. or I.P.D of Department of Panchakarma of I.P.G.T. and R.A., G.A.U., Jamnagar.</p><p>A special proforma including all the etiological factors of <italic>Prameha</italic> with <italic>Dushti Laskhanas</italic> of <italic>Dosha, Dushya, Srotas</italic>, etc. was made for assessing all the patients.</p><p>The patients were thoroughly questioned and examined on the basis of the proforma, and modern investigations like fasting blood sugar (FBS), postprandial blood sugar (PPBS), lipid profile, etc. were carried out to confirm the diagnosis.</p><sec id="sec2-2"><title>Inclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients having classical signs and symptoms of the disease according to <italic>Ayurveda</italic> as well as modern science.</p></list-item><list-item><p>Patients of <italic>Prameha</italic> having body mass index (BMI) 25-35 kg/m<sup>2</sup>.</p></list-item><list-item><p>Patients of non-insulin dependent Diabetes mellitus (NIDDM) with blood sugar levels: FBS 126&#x02013;220 mg/dl or PPBS 180&#x02013;300 mg/dl.</p></list-item><list-item><p>Patients in the age group of 20&#x02013;60 years.</p></list-item><list-item><p>Patients otherwise healthy and fit for <italic>Vamana</italic> and <italic>Virechana Karma</italic> as per the Ayurvedic classics.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Exclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Age &#x0003c;20 years and &#x0003e;60 years.</p></list-item><list-item><p>Patients of <italic>Prameha</italic> having BMI &#x0003c;25 and &#x0003e;35 kg/m<sup>2</sup> and disease chronicity for &#x0003e;10 years.</p></list-item><list-item><p>Patients of Type-1 Diabetes or the patients of Type-2 Diabetes taking insulin.</p></list-item><list-item><p>Patients having complications of Diabetes like nephropathy, retinopathy, diabetic foot, carbuncles, etc.</p></list-item><list-item><p>Patients having Diabetes in association with other endocrinopathies like pheochromocytoma, acromegaly, Cushing's syndrome, hyperthyroidism, etc.</p></list-item><list-item><p>Patients having drug- or chemical-induced Type-2 Diabetes, such as glucocorticoid or thyroid hormone induced, etc.</p></list-item><list-item><p>Patients with genetic syndromes associated with Type-2 Diabetes, such as Down's syndrome, Klinefelter's syndrome, Turner's syndrome, etc.</p></list-item><list-item><p>Patients with complications such as any cardiovascular diseases, renal diseases, carcinoma or any other disease effecting multiple body systems and pregnant women, etc.</p></list-item></list>
</p></sec><sec id="sec2-4"><title>Plan of study</title><p>Patients having classical signs and symptoms of <italic>Sthula Pramehi</italic> and known cases of Type-2 Diabetes were selected for the study after confirming the same by investigations. All the patients were randomly divided into two groups:</p></sec><sec id="sec2-5"><title>Group A: <italic>Vamana Karma</italic> followed by <italic>Shamana</italic></title><p><italic>Vamana</italic> followed by <italic>Samsarjana Karma</italic> and administration of <italic>Neem giloy satva</italic> capsule 500 mg/each capsule, was given to the patients, 1 capsule twice daily for 30 days.</p></sec><sec id="sec2-6"><title>Group B: <italic>Virechana karma</italic> followed by <italic>Shamana</italic></title><p><italic>Virechana</italic> followed by <italic>Samsarjana Karma</italic> and administration of <italic>Neem giloy satva capsule</italic>, keeping the same dose.</p></sec><sec id="sec2-7"><title>Criteria for assessment</title><p>Assessment was done on improvement in signs and symptoms with the help of suitable scoring method.</p></sec><sec id="sec2-8"><title>Criteria for the assessment of overall effect of the therapies</title><p>Total effect of the therapy was assessed considering the overall improvement in signs and symptoms. For this purpose, the following categories were maintained.</p><p>
<list list-type="order"><list-item><p>Complete remission: 100% relief in the signs and symptoms.</p></list-item><list-item><p>Marked relief: &#x02265;75% relief in the signs and symptoms.</p></list-item><list-item><p>Moderate relief: &#x02265;50-74% in the signs and symptoms.</p></list-item><list-item><p>Mild relief: 26-50% relief in the signs and symptoms.</p></list-item><list-item><p>No relief: &#x0003c;25% relief in the signs and symptoms were considered as unchanged.</p></list-item></list>
</p><p>Scoring pattern was adopted for signs and symptoms.[<xref ref-type="bibr" rid="ref4">4</xref>]</p></sec><sec id="sec2-9"><title>Statistical analysis</title><p>Paired &#x0201c;<italic>t</italic>&#x0201d; test was used for statistical analysis in <italic>Vamana</italic> as well as <italic>Virechana</italic> groups. For comparison between the both groups, unpaired &#x0201c;<italic>t</italic>&#x0201d; test was used.</p></sec></sec><sec id="sec1-3"><title>Observations and Results</title><p>46% patients were in the age group of 51&#x02013;60 years, 52% were females and 100% were married. 85% patients of this series were vegetarians and 97% were addicted to tea or coffee. 53% confirmed the family history of <italic>Prameha</italic> and maximum chronicity was 1&#x02013;3 years (53%). 38% were having <italic>Kapha-Pittaja Sharirika</italic> and 53% were having <italic>Tamah Pradhan Manasika Prakriti</italic>. All the patients had BMI between 25 and 35, and 41% were having <italic>Madhyama Jarana Shakti</italic> and 40% patients were having <italic>Krura Koshtha</italic>. Among the chief complaints of <italic>Prameha</italic>, maximum number of patients were having <italic>Prabhuta Mutrata</italic> (95%), <italic>Trishna dhikya</italic> (93%), <italic>Kshudha dhikya</italic> (82%), <italic>Kara-Pada Suptata</italic> (42%), <italic>Pindikodveshatan</italic> (83%), and <italic>Avila Mutrata</italic> (76%). Also, among the associated signs and symptoms of <italic>Prameha</italic>, maximum number of patients were having <italic>Maithune Ashakti</italic> (82%), followed by <italic>Nidra-tandra</italic> (63%), <italic>Alasya</italic> (71%), <italic>Swedatipravriti</italic> (44%) and <italic>Sheeta Priyata</italic> (19%). Maximum <italic>Matra</italic> of <italic>Triphala Siddha Tila Taila</italic> for <italic>Samyak Snehana</italic> was found to be 800&#x02013;1050 ml for 39% patients. 71% patients showed <italic>Uttam Shuddhi</italic> in group A, while 83% patients showed <italic>Maddhyama Shuddhi</italic> in group B.</p><p>In group A, <italic>Prabhuta Mutrata, Aavilmutrata, Kshudhadhikya, Trishnadhikya, Pindikodwestanam</italic>, and <italic>Nisha Mutrata</italic> (nocturia) remained controlled with highly significant results both after <italic>Samsarjana</italic> and <italic>Shamana</italic>, while complaints like <italic>Daurbalya</italic>, <italic>Nidra-tandra</italic>, and <italic>Alasya</italic> showed highly significant results after <italic>Samsarjana</italic> but showed significant results after <italic>Shamana</italic>. <italic>Kara-Pada Tala Daha</italic> and <italic>Klaibya</italic> were significantly controlled after <italic>Samsarjana</italic> and the control was highly significant after <italic>Shamana</italic>. <italic>Kara-Pada</italic>
<italic>Suptata</italic> was significant in both the conditions. Insignificant results were seen in <italic>Gala Talu Shosha</italic> on both the occasions. FBS both after <italic>Samsarjana</italic> and after <italic>Shamana</italic> was highly significant, whereas PPBS showed highly significant difference after <italic>Samsarjana</italic> but was significant after <italic>Shamana</italic>.</p><p>After <italic>Samsarjana</italic>, 6% patients showed marked relief, 61% had moderate relief, 23% showed mild relief and 11% had no relief in their chief and associated complaints. Here, 22% patients had controlled FBS while 17% patients had marked difference in PPBS. After <italic>Shamana</italic>, 50% patients showed marked relief in their complaints while 34% had moderate relief in their complaints. Again, FBS of 11% patients showed moderate difference and PPBS of 16% patients was under control.</p><p>In group B, highly significant relief was obtained in <italic>Prabhutmutrata, Aavilmutrata, Trishnadhikya, Kara pada tala daha, Nisha Mutrata, Atisweda</italic> and <italic>Pindikodwestana</italic>, while <italic>Nidra-Tandra</italic> and <italic>Alasya</italic> showed a highly significant result after <italic>Samsarjana</italic> but only mild relief was observed after <italic>Shamana</italic>. <italic>Gala talu Shosha</italic> was equally significant after <italic>Virechana</italic> and <italic>Shamana</italic>. In <italic>Klaibya</italic> relief was significant after <italic>Vamana</italic>, whereas it was highly significant after <italic>Shamana</italic>. FBS showed highly significant result both after <italic>Samsarjana</italic> and <italic>Shamana</italic> (<italic>P</italic>&#x0003c;0.001). PPBS, however, showed significant role both after <italic>Samsarjana</italic> and <italic>Shamana</italic> (<italic>P</italic>&#x0003c;0.02).</p><p>After <italic>Samsarjana</italic>, 30% patients had moderate relief while 60% had mild relief in their chief and associated complaints. After <italic>Shamana</italic>, 70% had moderate relief while 15% had mild relief. After <italic>Samsarjana</italic>, FBS of 40% and PPBS of 20% patients was under control, while after Shamana FBS of 30% and PPBS of 20% patients was controlled [Tables <xref ref-type="table" rid="T1">1</xref>&#x02013;<xref ref-type="table" rid="T3">3</xref> and Figures <xref ref-type="fig" rid="F1">1</xref>&#x02013;<xref ref-type="fig" rid="F3">3</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparative effects of both <italic>Karma</italic> (<italic>Vamana</italic> and <italic>Virechana</italic>) on the chief complaints in patients of <italic>Sthula Pramehi</italic> (by unpaired &#x0201c;<italic>t</italic>&#x0201d; test)</p></caption><graphic xlink:href="Ayu-32-536-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparative effects of both <italic>Karma</italic> (<italic>Vamana</italic> and <italic>Virechana</italic>) on the associated symptoms in patients of <italic>Sthula Pramehi</italic> (by unpaired &#x0201c;<italic>t</italic>&#x0201d; test)</p></caption><graphic xlink:href="Ayu-32-536-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparative effects of both <italic>Karma</italic> (<italic>Vamana</italic> and <italic>Virechana</italic>) on blood sugar level in patients of <italic>Sthula Pramehi</italic> (by unpaired &#x0201c;<italic>t</italic>&#x0201d; test)</p></caption><graphic xlink:href="Ayu-32-536-g003"/></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Percentage relief on chief complaint &#x02013; After completion of treatment</p></caption><graphic xlink:href="Ayu-32-536-g004"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>% Relief on associated symptoms &#x02013; After completion of treatment</p></caption><graphic xlink:href="Ayu-32-536-g005"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Effect on blood sugar levels &#x02013; After completion of treatment</p></caption><graphic xlink:href="Ayu-32-536-g006"/></fig></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p><italic>Madhumeha</italic> (Diabetes) has turned out to be the biggest &#x0201c;<italic>silent killer</italic>&#x0201d; in today's world. As per the estimate of WHO in its report, at least 171 million people presently suffer from diabetes and this number is expected to rise to 366 million by the year 2030. In spite of tremendous advancement in the modern system of medicine, i.e. oral hypoglycemic agent and insulin, still an ideal drug which can cure Diabetes is not available. It is mandatory to give <italic>Deepana-Pachana</italic> drug before <italic>Aabhyantara</italic>
<italic>Snehapan</italic> because their inherent properties of <italic>Amapachana</italic> and increasing the quantum of <italic>Agni</italic>.[<xref ref-type="bibr" rid="ref5">5</xref>] <italic>Amapachana</italic> helps to reduce the <italic>Picchilta</italic> of morbid matter so that they can be easily dislodged; that's why <italic>Trikatu Churna</italic> has been selected as it has <italic>Deepan-Pachana</italic> as well as <italic>Pramehaghna</italic> properties.</p><p>47% of registered patients belonged to the age group of 51&#x02013;60 years. This data favor the view of modern science that Type-2 Diabetes is primarily a disease of middle and old age, but obese population may get it at an earlier age.[<xref ref-type="bibr" rid="ref6">6</xref>]</p><p>53% of patients had a positive family history and also chronicity of 1&#x02013;3 years, as <italic>Prameha</italic> is an <italic>Aanushangi</italic> as well as <italic>Beej doshaj Vyadhi</italic>. So, it mostly affects middle-aged people; living a sedentary life and a positive family history plays a major role in its development.</p><p>During the study it was observed that, <italic>Vamana Karma</italic> is effective in pacifying symptoms like <italic>Prabhuta Mutrata</italic> and <italic>Avila Mutrata</italic>. Because both symptoms are mainly due to <italic>Kapha Prakopa</italic> and <italic>Abadha Meda</italic>, and for this <italic>Vamana</italic> is the choice of treatment.</p><p>In symptoms such as <italic>Kara Pada Tala Daha</italic>, <italic>Atisweda</italic> and <italic>Nidra-Tandra</italic>, <italic>Virechana</italic> showed good relief though the result was insignificant. It is because <italic>Kara Pada Tala Daha</italic> and <italic>Atisweda</italic> are <italic>Pitta</italic> predominant features and <italic>Virechana</italic> is best for <italic>Pitta</italic>. <italic>Nidra-Tandra</italic> is a <italic>Kapha</italic> predominant symptom, but in <italic>Prameha</italic>, <italic>Sthan-Sanshraya</italic> of <italic>Kapha</italic> is in <italic>Basti Pradesha</italic>. So, this symptom is also relieved by <italic>Virechana</italic>.</p><p>It seems that <italic>Vamana</italic> by reducing <italic>Kapha</italic> and <italic>Meda</italic> helps to minimizing insulin resistance, while <italic>Virechana</italic> by lowering the hepatic glucose production helps to control blood sugar.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusion</title><p><italic>Vamana</italic> works well on <italic>Kapha</italic> dominant <italic>Lakshana</italic> like <italic>Prabhuta Mutrata</italic>, and <italic>Aavil Mutrata</italic>, while <italic>Virechana</italic> subsides <italic>Pitta</italic> dominant <italic>Lakshana</italic> like <italic>Kara Pada Tala Daha</italic> and <italic>Atisweda</italic>. Symptoms like <italic>Kara-pada Suptata, Kshudadhikya, Trishnaadhikya, Gala Talu Shosha</italic> and <italic>Pindikodwestana</italic> are significantly controlled by both <italic>Vamana</italic> and <italic>Virechana</italic>.</p><p>Though both the procedures relieve the symptoms, it is <italic>Vamana</italic> that provides more relief than <italic>Virechana</italic>. <italic>Vamana</italic> reduces the levels of FBS, PPBS in comparison to <italic>Virechana</italic>.</p></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><article-title>Vagbhata</article-title><source>Astanga Hridaya, Sutra Sthana, Doshopkramaniya Adhyaya</source><year>2008</year><volume>13</volume><edition>9th ed</edition><issue>29</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Sanskrit Sansthan</publisher-name><fpage>133</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shastri</surname><given-names>Ambikadatt</given-names></name><name><surname>Ratnavali</surname><given-names>Bhaisajya</given-names></name></person-group><source>Prameha Chikitsha Adhyaya</source><year>2008</year><volume>37</volume><edition>19th ed</edition><issue>9</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Sanskrit Sansthana</publisher-name><fpage>720</fpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><article-title>Charaka</article-title><source>Charaka Samhita, Vimana Sthana, Rog Bishag jitia Adhyaya</source><year>2007</year><volume>8</volume><issue>84</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Sanskrit Sansthana</publisher-name><fpage>274</fpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>J</given-names></name><name><surname>Shukla</surname><given-names>VD</given-names></name></person-group><source>A Comparative Clinical Study Of Nyagrodhadi Ghanavati and Virechana Karma in the management of Madhumeha (D.M), Kaya chikitsha</source><year>2007</year><publisher-loc>Jamnagar</publisher-loc><publisher-name>IPGT and RA</publisher-name></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Dutt</surname><given-names>TR</given-names></name></person-group><source>Astang Sangrah, Sutra Sthana, Sneha vidhinam Adhyaya</source><year>1999</year><volume>25</volume><issue>45</issue><publisher-loc>Delhi</publisher-loc><publisher-name>Chaukhamba Sanskrit Pratisthan</publisher-name><fpage>457</fpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="webpage"><article-title>World Health Organization</article-title><date-in-citation>Last cited on 2010 May 10</date-in-citation><comment>Available from:
<uri xlink:type="simple" xlink:href="http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/">http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/</uri></comment></element-citation></ref></ref-list></back></article>